AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)

Protocol: 
AAAQ8705
Phase: 
I/II

AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)

Are you Eligible? (Inclusion Criteria)

-Subjects must be at least 1 year and up to 21 years of age at the time of
study entry.
-Patients must have a histological diagnosis of Acute Myeloid Leukemia.
-Patients must be in first marrow relapse and patients must not have received
prior re-induction therapy.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States